BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HBI-2438 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HBI-2438\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05485974-2509@assetmemo.bio
DTSTAMP:20261121T005736Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HBI-2438: Phase 1 readout est. (NCT05485974)
DESCRIPTION:HBI-2438\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Dose
  Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS
  G12C Mutation\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hbi-2438#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05485974
URL:https://assetmemo.bio/drug/hbi-2438#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
